Innovations in bioengineering are reshaping therapeutic delivery and diagnostics. Carnegie Mellon scientists developed biological microscale robots, "AggreBots," from human lung cells capable of targeted interventions. Separately, a hybrid electrical stimulation-robotic device advances gait training in neurological disorder patients, combining neurophysiological and robotic methods for rehabilitation. Additionally, AI-powered single-cell analysis platforms enable rapid, quantitative intracellular delivery and evaluation, promising enhanced personalized medicine applications.